A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Completed · Phase 3 · Has a placebo group

Conditions studied: Psoriasis

In brief

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Key facts

Study ID

NCT03535194

Run by

Eli Lilly and Company

People needed

1484

Starts

2018-06-26

Expected to finish

2020-06-03

Last updated by the study team

2021-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must have chronic plaque psoriasis for at least 6 months.

You may not qualify if…

• Participant must not be breastfeeding or nursing woman.
• Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.
• Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.
• Participant must not have any other skin conditions (excluding psoriasis).
• Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).
• Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.
• Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).

Where it is running

• Bakersfield Dermatology and Skin Cancer Medical Group — Bakersfield, California, United States
• David Stoll, M.D. — Beverly Hills, California, United States
• California Dermatology and Clinical Research Institute — Encinitas, California, United States
• Tien Q. Nguyen, MD inc. DBA First OC Dermatology — Fountain Valley, California, United States
• Keck School of Medicine University of Southern California — Los Angeles, California, United States
• Dermatology Clinical Trials — Newport Beach, California, United States
• San Luis Dermatology & Laser Clinic, Inc — San Luis Obispo, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• Dermatologic Surgery Specialists, PC — Macon, Georgia, United States
• Medaphase Inc — Newnan, Georgia, United States
• Meridian Clinical Research — Savannah, Georgia, United States
• Treasure Valley Dermatology — Boise, Idaho, United States
• University Dermatology — Darien, Illinois, United States
• Arlington Dermatology — Rolling Meadows, Illinois, United States
• Dawes Fretzin Clinical Research — Indianapolis, Indiana, United States
• The Indiana Clinical Trials Center, PC — Plainfield, Indiana, United States
• The South Bend Clinic — South Bend, Indiana, United States
• Dermatology Specialist — Louisville, Kentucky, United States
• DelRicht Research — Baton Rouge, Louisiana, United States
• Dermatology and Skin Cancer Specialists — Rockville, Maryland, United States
• Lawrence J Green, M.D, LLC — Rockville, Maryland, United States
• ORA, Inc — Andover, Massachusetts, United States
• Central Dermatology PC — St Louis, Missouri, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.